|
Pan-PI3K
|
BKM120
|
Novartis
|
ATP-competitive
|
| |
XL-147
|
Exelixis
|
ATP-competitive
|
| |
PX-866
|
Oncothyreon
|
ATP-competitive
|
| |
GDC-0941
|
Genentech/Roche
|
ATP-competitive
|
| |
CH5132799
|
Chugai Pharma
|
ATP-competitive
|
|
p110δ-specific
|
CAL-101
|
Calistoga
|
ATP-competitive
|
|
p110α-specific
|
BYL719
|
Novartis
|
ATP-competitive
|
| |
GDC-0032
|
Genentech/Roche
|
ATP-competitive
|
| |
INK-1117
|
Intellikine
|
ATP-competitive
|
|
PI3K/mTOR
|
PKI-587
|
Pfizer
|
ATP-competitive
|
| |
BEZ235
|
Novartis
|
ATP-competitive
|
| |
BGT226
|
Novartis
|
ATP-competitive
|
| |
PF-4691502
|
Pfizer
|
ATP-competitive
|
| |
GDC-0980
|
Genentech/Roche
|
ATP-competitive
|
| |
XL-765
|
Exelixis
|
ATP-competitive
|
| |
SF1126
|
Semafor
|
ATP-competitive/peptide-conjugate
|
| |
GSK1059615
|
GSK
|
ATP-competitive
|
|
TORC1
|
Everolimus (RAD001)
|
Novartis
|
Indirect, FKBP12-mediated
|
| |
Temsirolimus (CCI-779)
|
Wyeth/Pfizer
|
Indirect, FKBP12-mediated
|
| |
Ridaferolimus (AP-23573)
|
Merck/Ariad
|
Indirect, FKBP12-mediated
|
|
TORC1/TORC2
|
INK-128
|
Intellikine
|
ATP-competitive
|
| |
OSI-027
|
OSI Pharm.
|
ATP-competitive
|
| |
AZD-8055
|
Astrazeneca
|
ATP-competitive
|
|
AKT
|
AZD5363
|
Astrazeneca
|
ATP-competitive
|
| |
GDC-0068
|
Genentech/Roche
|
ATP-competitive
|
| |
GSK690693
|
GSK
|
ATP-competitive
|
| |
MK-2206
|
Merck
|
Allosteric
|
| |
VQD002
|
Vioquest
|
ATP-competitive
|
